Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow.

Slides:

Advertisements

Similar presentations

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

Advertisements

Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation Nirali N. Shah, Michael J. Borowitz,

Reduced-Intensity Conditioning Regimens for Allogeneic Transplantation in Children with Acute Lymphoblastic Leukemia Michael R. Verneris, Mary Eapen,

Extramedullary Relapse of Acute Leukemia after Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical.

Norovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation Recipients: Incidence, Risk Factors, and Outcome Joseph Delano F. Robles, Daniel.

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens by Menachem Bitan,

Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and.

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

Outcome of Myeloablative Conditioning and Unrelated Donor Hematopoietic Cell Transplantation for Childhood Acute Lymphoblastic Leukemia in Third Remission

Hematopoietic Stem Cell Transplantation for Refractory or Recurrent Non-Hodgkin Lymphoma in Children and Adolescents Thomas G. Gross, Gregory A. Hale,

Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation

Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation Claudio G. Brunstein, Effie W. Petersdorf,

Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age Years with Acute Myelogenous Leukemia in First.

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Major ABO Blood Group Mismatch Increases the Risk for Graft Failure after Unrelated Donor Hematopoietic Stem Cell Transplantation Mats Remberger, Emma.

Isolated Extramedullary Relapse of Acute Leukemia after Allogeneic Stem Cell Transplantation: Different Kinetics and Better Prognosis than Systemic Relapse

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Comparison of Outcomes after HLA-Matched Sibling and Unrelated Donor Transplantation for Children with High-Risk Acute Lymphoblastic Leukemia Mei-Jie.

Sabina Kersting, Leo F. Verdonck

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Betty T. Tran, Abigail Halperin, Jason W. Chien

Impact of Pretransplantation Risk Factors on Post Transplantation Outcome of Patients with Acute Myeloid Leukemia in Remission after Haploidentical Hematopoietic.

Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions Darius Sairafi, Mats Remberger, Michael.

Favorable Outcome for Infant Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation David A. Jacobsohn, Brad Hewlett, Elaine Morgan,

Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission Jennifer L. Holter.

T Cell–Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar.

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

A Comparison of Cyclophosphamide and Total Body Irradiation with Etoposide and Total Body Irradiation as Conditioning Regimens for Patients Undergoing.

The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia Jennifer.

Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in.

Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:

Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program Margaret L.

Race and Socioeconomic Status Influence Outcomes of Unrelated Donor Hematopoietic Cell Transplantation K. Scott Baker, Stella M. Davies, Navneet S. Majhail,

Unrelated Cord Blood Transplantation in Adult and Pediatric Acute Lymphoblastic Leukemia: Effect of Minimal Residual Disease on Relapse and Survival

Busulfan/Melphalan/Antithymocyte Globulin Followed by Unrelated Donor Cord Blood Transplantation for Treatment of Infant Leukemia and Leukemia in Young.

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

A Prospective Multicenter Trial of Peripheral Blood Stem Cell Sibling Allografts for Acute Myeloid Leukemia in First Complete Remission Using Fludarabine-Cyclophosphamide.

Impact of Conditioning Regimen in Allogeneic Hematopoetic Stem Cell Transplantation for Children with Acute Myelogenous Leukemia beyond First Complete.

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Single Cord Blood Combined with HLA-Mismatched Third Party Donor Cells: Comparable Results to Matched Unrelated Donor Transplantation in High-Risk Patients.

Incidence, Predisposing Factors, and Outcome of Engraftment Syndrome in Pediatric Allogeneic Stem Cell Transplant Recipients Irene Schmid, Daniel Stachel,

Allogeneic Hematopoietic Cell Transplantation in Children with Relapsed Acute Lymphoblastic Leukemia Isolated to the Central Nervous System Paul D. Harker-Murray,

Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure Mouhab Ayas, Mary Eapen, Jennifer Le-Rademacher,

Feasibility of Treating Post-Transplantation Minimal Residual Disease in Children with Acute Leukemia Nirali N. Shah, Michael J. Borowitz, Nancy C. Robey,

Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High- Risk Acute Lymphoblastic Leukemia Samer A. Srour, Denái R. Milton,

Hematopoietic Cell Transplantation for Children with Acute Lymphoblastic Leukemia in Second Complete Remission: Similar Outcomes in Recipients of Unrelated.

Impact of Donor and Recipient Sex and Parity on Outcomes of HLA-Identical Sibling Allogeneic Hematopoietic Stem Cell Transplantation Alison W. Loren,

Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation Merav Bar, Weigang Tong, Megan Othus,

The Outcome of Allogeneic Hematopoietic Cell Transplantation for Children with FMS- Like Tyrosine Kinase 3 Internal Tandem Duplication–Positive Acute Myelogenous.

Comparison of Outcomes after Transplantation of G-CSF–Stimulated Bone Marrow Grafts versus Bone Marrow or Peripheral Blood Grafts from HLA-Matched Sibling.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Allogeneic Bone Marrow Transplantation in First Remission for Children with Ultra-high- risk Features of Acute Lymphoblastic Leukemia: A Children’s Oncology.

Kinetics and Risk Factors of Relapse after Allogeneic Stem Cell Transplantation in Children with Leukemia: A Long-Term Follow-Up Single-Center Study

Johann K. Hitzler, Wensheng He, John Doyle, Mitchell Cairo, Bruce M

Richard Mitchell, John E. Wagner, Claudio Brunstein, Qing Cao, David H

Risk Factors Affecting Outcome of Second HLA-Matched Sibling Donor Transplantations for Graft Failure in Severe Acquired Aplastic Anemia John T. Horan,

T Cell–Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an.

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,

Blood and Marrow Transplant Handbook

Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease Haydar Frangoul, Li.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation Nirali N. Shah, Michael J. Borowitz,

Mammen Chandy Biology of Blood and Marrow Transplantation

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

Mary Eapen Biology of Blood and Marrow Transplantation

Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less David F. Stroncek, Bronwen E.

Presentation transcript:

Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research Michael J. Burke, Michael R. Verneris, Jennifer Le Rademacher, Wensheng He, Hisham Abdel-Azim, Allistair A. Abraham, Jeffery J. Auletta, Mouhab Ayas, Valerie I. Brown, Mitchell S. Cairo, Ka Wah Chan, Miguel A. Diaz Perez, Christopher C. Dvorak, R. Maarten Egeler, Lamis Eldjerou, Haydar Frangoul, Gregory M.T. Guilcher, Robert J. Hayashi, Ahmed Ibrahim, Kimberly A. Kasow, Wing H. Leung, Richard F. Olsson, Michael A. Pulsipher, Niketa Shah, Nirali N. Shah, Elizabeth Thiel, Julie-An Talano, Carrie L. Kitko Biology of Blood and Marrow Transplantation Volume 21, Issue 12, Pages 2154-2159 (December 2015) DOI: 10.1016/j.bbmt.2015.08.023 Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 (A) Cumulative incidence of TRM was 13% (95% CI, 9% to 18%) at day 100, 21% (95% CI, 16% to 26%) at 1 year, and 24% (95% CI, 18% to 30%) at 3 years. (B) Probability of DFS at 3 years was 46% (95% CI, 39% to 52%). Biology of Blood and Marrow Transplantation 2015 21, 2154-2159DOI: (10.1016/j.bbmt.2015.08.023) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 (A) Cumulative incidence of relapse at 3 years for patients with an isolated extramedullary relapse (central nervous system/testes) was 15% (95% CI, 5% to 28%) compared with 45% (95% CI, 32% to 58%) for patients with isolated or combined BM relapse (P < .001). (B) Probability of DFS at 3 years for patients with an isolated extramedullary relapse (central nervous system/testes) was 56% (95% CI, 39% to 72%) compared with 35% (95% CI, 23% to 47%) for patients with isolated or combined BM relapse (P = .05). Biology of Blood and Marrow Transplantation 2015 21, 2154-2159DOI: (10.1016/j.bbmt.2015.08.023) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 (A) Cumulative incidence of relapse at 3 years for patients receiving HLA-matched sibling BM was 34% (95% CI, 24% to 45%), unrelated BM/PBSCs was 34% (95% CI, 23% to 46%), and unrelated UCB was 24% (95% CI, 15% to 34%) (P = .26). (B) Probability of DFS at 3 years for patients receiving HLA-matched sibling BM was 48% (95% CI, 37% to 59%), unrelated BM/PBSCs was 37% (95% CI, 25% to 49%), and unrelated UCB was 50% (95% CI, 39% to 61%) (P = .25). Biology of Blood and Marrow Transplantation 2015 21, 2154-2159DOI: (10.1016/j.bbmt.2015.08.023) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions